(Date:10/6/2008)... /PRNewswire-FirstCall/ -- HealthSouth,Corporation...previously,publicized investor meeting in New York...08 at 8:30 a.m. EST at the Grand Hyatt New York, l...ng is as follows:, 8:00 a.m. Continental Brea...f Executive Officer -- HealthSouth Ov...
(Date:10/6/2008)...y personnel and their family members can take,anon...nts, BOSTON, Oct. 6 /PRNewswire-USNewswire/ -- Mi...ers and their families that are unique and,difficu...tances matters get,worse and one problem can trigg...wise to check things out to see what is really hap...
(Date:10/6/2008)... at the University of California, San Diego School...upplements bolsters production of a protective che...vent skin infections that are a common result of a..., The study led by Richard Gallo, M.D., Ph.D., ... Dermatology at the UCSD School of Medicine and th...
(Date:10/6/2008)...ire/ -- A special supplement of the Oct. 15,journa... low- and,middle-income countries to implement bre...ommon disease among women worldwide., "Guidelines...l -,Implementation" developed by the Breast Health... of resource allocation -- based on countries,ove...
Breaking Medicine News(10 mins):Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Oral vitamin D may help prevent some skin infections 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 2Health News:International Implementation of Breast Health Guidelines for Developing Countries Published by Cancer 3(Date:10/6/2008)... - Data Presented at ACG Annual Scientific C...- Ironwood Pharmaceuticals,(formerly Microbia) tod...reclinical studies delineating the role that cycli...ing intestinal pain. These studies,demonstrate tha...odel of,intestinal hyperalgesia and desensitizes c...
(Date:10/6/2008)... Results from Phase 3b Studies with Durezol Dosed .../ -- Sirion Therapeutics, Inc., a,privately held o...nced,today that Durezol(TM) (difluprednate ophthal... Durezol, which was approved by the U.S. Food and,...thalmic corticosteroid,indicated for the treatment...
(Date:10/6/2008)...More than 60 percent of moderate to severe patient...rcent achieved endoscopic remission at Week 10,in ...the American College,of Gastroenterology (ACG) Ann...Newswire/ -- UCB today presented data from a,large...vement in Crohn,s,disease (CD) with a biologic com...
(Date:10/6/2008)...SEATTLE, Oct. 6 /- Dendreon... call today, Monday, October 6, 2008 at 9:00 AM,ET... analysis of its IMPACT,(IMmunotherapy for Prostat...clinical trial of PROVENGE(R) (sipuleucel-T), the ...erapy for the treatment of advanced prostate,cance...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2TGen and Washington University researchers discover new approach to treating endometrial cancer 4660 1TGen and Washington University researchers discover new approach to treating endometrial cancer 4660 2TGen and Washington University researchers discover new approach to treating endometrial cancer 4660 3ICERx org Activated to Provide Emergency Access to Prescription Medication Information for Hurricane Gustav Evacuees 25915 1American Red Cross Relief Efforts Underway for Gustav 25910 1American Red Cross Relief Efforts Underway for Gustav 25910 2New master switch found in the brain that regulates appetite and reproduction 4655 1New master switch found in the brain that regulates appetite and reproduction 4655 2New master switch found in the brain that regulates appetite and reproduction 4655 3New master switch found in the brain that regulates appetite and reproduction 4655 4...ire-FirstCall/ - Bradmer,Pharmaceuticals Inc., a b...ent and commercialization of cancer therapies, tod...ependent team in,Basel, Switzerland validates tena...lopment of new treatments for glioblastoma,multifo...oss of NOTCH2 gene,positively predicts survival in...
...2007 - AVI BioPharma, Inc.,(Nasdaq:AVII) announced... target patient enrollment and released six-month,...n as Appraisal.,The trial, currently being held in...Neugene(R) antisense drug Resten-MP(TM), when,used...bare metal,stents, in the prevention of cardiovasc...
Other Medicine Technology:Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 2Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 3Molecular Target of Bradmer's Neuradiab Further Validated by,Independent Findings 4AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2Straight heavy shafts with delicate 7 mm tying platform. Sharp pointed tips for removing fine sutures. Wide serrated handle with polished finish. Overall length 4.1 inches.
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches.
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required.
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches.
Medicine Products: